TCR2 Therapeutics Inc. (NASDAQ:TCRR) changes shares on Friday trading session, with a change of -1.30% or -$0.21 shares. The trading starts at $16.23 and closed at $16.10 throughout the day. The trading session low price was $15.89 and day high was $17.02 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.24 million while its average volume is 107.71K. In other hand, the TCRR market cap reached to $371.51M. While, its current target price is $15.89 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 11.59% and up 57.80% for month. Its quarterly performance was 130.62% above, while its half year performance is down -5.19%. TCRR yearly performance stood at positive 1.92% and rise 11.27% for year-to-date. Current recommendation for TCR2 Therapeutics Inc. is 1.70.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. TCRR EPS (TTM) for 12-month is -2.22. EPS for this year is -79.70%, while for the next year its value is -2.94. Its EPS Q/Q reached 74.10%. It has an EPS of next five years will be down 0.00%.
Let’s take a look on the analyst recommendations on TCRR for the current month and previous month. For the current month, 5 of 6 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $16.00-$35.00. Average target price for TCRR was reached at $24.67.
MPM Asset Management, LLC, MPM ONCOLOGY IMPACT MANAGEMENT LP and Redmile Group, LLC are the top three holders in TCR2 Therapeutics Inc. (TCRR) stock. On Mar 30, 2020, MPM Asset Management, LLC has 4.05 million shares which valued 31.35 million. On Mar 30, 2020, MPM ONCOLOGY IMPACT MANAGEMENT LP owned 3.37 million shares which valued at 26.09 million. On Mar 30, 2020, Redmile Group, LLC has a total of 1.77 million shares which valued at 13.68 million. In the end, Redmile Group, LLC have 7.34% shares outstanding of TCR2 Therapeutics Inc. (TCRR) on Mar 30, 2020. The insider ownership moved to 0.20% and institutional holding shifted to 84.70%.
The company posted an EPS (TTM) of -2.22. According to the most recent quarter report on (Jun 2020), 6 analysts estimated an average EPS of -0.61, while -0.46 EPS posted a year ago period. Analyst Estimated EPS for TCRR published in the report was -0.73–0.43 during the same period. Comparing with last year, the average estimated EPS was -0.46 which is higher than -0.65 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for TCRR rise 18.51% for period of 200 days. SMA for 50 days was 41.14% which is showing green signal, while SMA-20 was 21.51%. The moving average value for TCR2 Therapeutics Inc. (TCRR) is 12.37 and 11.83 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in TCRR stock. On Mar 20, Gibson Neil W, Director, sold 648 trading shares at the cost of $7.94, which valued at 5145.0. On Mar 19, Gibson Neil W, Director, sold 3,140 shares at the cost of $7.41, with total shares of 648. On Mar 18, Gibson Neil W, Director, sold 3,120 shares at the cost of 6.83. After this transaction, Gibson Neil W total shares reached to 3,788 which valued at 21310.0.